Thomas Spitznagel - Jul 16, 2021 Form 4 Insider Report for MACROGENICS INC (MGNX)

Role: Sr VP, BPD & Manufacturing
Signature: /s/ Lynn Cilinski, Attorney-in-Fact
Stock symbol: MGNX
Transactions as of: Jul 16, 2021
Transactions value $: -$125,050
Form type: 4
Date filed: 7/20/2021, 05:09 PM
Next filing: Feb 24, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	MGNX	Common Stock	Options Exercise	$37.6K	+5K		$7.51	5K	Jul 16, 2021	Direct
transaction	MGNX	Common Stock	Sale	-$125K	-5K	-100%	$25.01	0	Jul 16, 2021	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	MGNX	Employee stock option (right to buy)	Options Exercise	-$37.6K	-5K	-11.86%	$7.51	37.1K	Jul 16, 2021	Common Stock	5K	$7.51	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 10, 2021.
F2	This transaction was executed in multiple trades at prices ranging from $25.00 to $25.04. The reporting person undertakes to provide to MacroGenics, Inc., any security holder of MacroGenics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3	12.5% of the shares underlying the grant become (or became) exercisable on the date reflected and an additional 6.25% of the shares underlying the grant become (or became) exercisable on the first day of each three-month period thereafter.